Whether CD44 is an applicable marker for glioma stem cells

Area of Science:

• Neuro-oncology
• Cancer Biology
• Cell Biology

Background:

• Glioblastoma multiforme (GBM) is a highly aggressive brain tumor.
• Hyaluronan (HA) and its receptor CD44 are implicated in GBM.
• CD44 is often considered a cancer stem cell (CSC) marker, but conflicting data exists regarding its role in glioma stem cells (GSCs).

Purpose of the Study:

• To investigate the role of CD44 as a marker for glioma stem cells (GSCs).
• To determine if CD44 expression levels correlate with GSC properties and patient prognosis.

Main Methods:

• Manipulated CD44 expression in glioma cells using CD44 knockdown (CD44kd) and HA supplementation (HA+).
• Assessed cell proliferation, cell cycle progression, differentiation markers (GFAP), sphere formation, and stem cell markers (CD133, nestin, Oct4).
• Examined CD44 expression at the invasive rim of rat glioma specimens.

Main Results:

• CD44kd suppressed cell proliferation and induced GSC traits, including reduced GFAP and increased sphere formation and stem cell marker expression.
• HA+ treatment, which reduced CD44 expression, also increased GSC properties.
• Conversely, HA+ facilitated differentiation in GSC-like cells.
• CD44 was preferentially expressed at the invasive rim of gliomas.

Conclusions:

• CD44 is not an appropriate marker for identifying GSCs, as CD44-low cells exhibit more GSC traits.
• CD44 expression may be more critical for glioma cell invasion and migration than for maintaining stemness.